Suppr超能文献

使用去势大鼠和未去势大鼠对一种新型口服活性小分子促性腺激素释放激素(GnRH)拮抗剂进行生物学特性研究。

Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.

作者信息

Anderes Kenna L, Luthin David R, Castillo Rosemary, Kraynov Eugenia A, Castro Mary, Nared-Hood Karen, Gregory Margaret L, Pathak Ved P, Christie Lance C, Paderes Genevieve, Vazir Haresh, Ye Qiang, Anderson Mark B, May John M

机构信息

Research Pharmacology, Pfizer Global Research and Development-La Jolla/Agouron Pharmaceuticals, Inc., 10724 Science Center Drive, San Diego, CA 92121, USA.

出版信息

J Pharmacol Exp Ther. 2003 May;305(2):688-95. doi: 10.1124/jpet.102.046656. Epub 2003 Jan 24.

Abstract

Gonadotropin-releasing hormone (GnRH) receptor antagonists have potential in treating numerous hormone-dependent pathologies including cancers of the prostate, breast, and ovary, endometriosis, and fertility disorders. An unmet clinical need exists for an orally available GnRH receptor antagonist. Guided by structure-activity relationships, ligand-based targeted library designs, and biomarker measurements, our discovery efforts have yielded a novel, small molecule GnRH receptor antagonist, 5-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)-2-furamide (CMPD1). CMPD1 bound with low nanomolar affinities to human, rat, and mouse GnRH receptors (6.0, 3.8, and 2.2 nM, respectively). CMPD1 was more than 100-fold selective for GnRH receptors versus various G-protein-coupled receptors and other enzymes and ion channels. In cells expressing recombinant rat GnRH receptors, CMPD1 was a competitive antagonist of GnRH-stimulated increases in extracellular acidification rates in Cytosensor microphysiometer assays. In cells expressing recombinant human GnRH receptors, CMPD1 was a potent inhibitor of GnRH-stimulated total inositol phosphate accumulation. The effects of CMPD1 on circulating levels of luteinizing hormone (LH) and testosterone were studied in castrated and intact male rats, respectively. Intravenous and oral administration of CMPD1 dose dependently suppressed GnRH-mediated elevations of LH in castrated male rats and testosterone in gonad-intact male rats. Moreover, CMPD1, when given at 20 mg/kg i.v. to intact male rats, inhibited the elevations of LH and testosterone stimulated by the superagonist of GnRH, [d-Ala(6), des-Gly(10)]GnRH (GnRH-A). These data suggest that CMPD1 is a potent, selective, orally active GnRH receptor antagonist that may have potential application as a therapeutic agent for treating hormone-dependent cancers and diseases.

摘要

促性腺激素释放激素(GnRH)受体拮抗剂在治疗多种激素依赖性疾病方面具有潜力,这些疾病包括前列腺癌、乳腺癌、卵巢癌、子宫内膜异位症和生育障碍。目前临床上对口服可用的GnRH受体拮抗剂仍有未满足的需求。在构效关系、基于配体的靶向文库设计和生物标志物测量的指导下,我们的研发工作产生了一种新型小分子GnRH受体拮抗剂,5-[(3,5,5,8,8-五甲基-5,6,7,8-四氢-2-萘基)甲基]-N-(2,4,6-三甲氧基苯基)-2-呋喃甲酰胺(化合物1)。化合物1与人、大鼠和小鼠的GnRH受体结合亲和力低至纳摩尔级别(分别为6.0、3.8和2.2 nM)。与各种G蛋白偶联受体以及其他酶和离子通道相比,化合物1对GnRH受体的选择性超过100倍。在表达重组大鼠GnRH受体的细胞中,在细胞传感器微生理计测定中,化合物1是GnRH刺激的细胞外酸化率增加的竞争性拮抗剂。在表达重组人GnRH受体的细胞中,化合物1是GnRH刺激的总肌醇磷酸积累的有效抑制剂。分别在去势和完整雄性大鼠中研究了化合物1对黄体生成素(LH)和睾酮循环水平的影响。静脉内和口服给予化合物1剂量依赖性地抑制去势雄性大鼠中GnRH介导的LH升高以及性腺完整雄性大鼠中睾酮升高。此外,当以20 mg/kg静脉内给予完整雄性大鼠时,化合物1抑制GnRH超激动剂[d-Ala(6),des-Gly(10)]GnRH(GnRH-A)刺激的LH和睾酮升高。这些数据表明,化合物1是一种强效、选择性、口服活性的GnRH受体拮抗剂,可能具有作为治疗激素依赖性癌症和疾病的治疗剂的潜在应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验